# US 2026/0092279 A1 · Double-stranded rnai agents and compositions for reducing expression of angiopoietin-like 3 (angptl3) and methods of use thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0092279 A1
- Document ID: US20260092279A1
- Status: Published application
- Kind: A1
- Application number: 19/344,040
- Filed: 2025-09-29
- Published: 2026-04-02
- Earliest claimed: 2024-02-09
- Assignees: AstraZeneca AB; Silence Therapeutics GmbH
- Applicants: Astrazeneca AB; Silence Therapeutics GmbH
- Inventors: Ariana FOINQUINOS; Eva HURT-CAMEJO; Xiao-Rong PENG; Eliot MORRISON; Stavros GIANNAKOPOULOS; Sibylle DAMES; Timo JOHANNSSEN; Lucas BETHGE; Steffen SCHUBERT; Marie WIKSTRÖM LINDHOLM
- Web page: https://patentgrep.com/patent/US20260092279A1

## CPC

- C12N 15/1136: {against growth factors, growth regulators, cytokines, lymphokines or hormones}
- A61P 3/06: Antihyperlipidemics
- C12N 2310/14: interfering nucleic acids [NA]
- C12N 2310/315: Phosphorothioates
- C12N 2310/322: 2'-R Modification
- C12N 2310/333: Modified A
- C12N 2310/3341: 5-Methylcytosine
- C12N 2310/335: Modified T or U
- C12N 2310/336: Modified G
- C12N 2310/343: having patterns, e.g. ==--==--==--
- C12N 2310/346: having a combination of backbone and sugar modifications
- C12N 2310/351: Conjugate
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

There are disclosed certain double-stranded RNA (dsRNA) or siRNA agents for inhibition of angiopoietin-like 3 gene expression, compositions that include angiopoietin-like 3 agents and methods of use thereof. The double-stranded RNA (dsRNA) or siRNA agents are particularly useful in the treatment or prophylaxis of cardiovascular disease and metabolic conditions as well as in the treatment of heart failure and chronic kidney disease.

## Claims

### Claim 1

An angiopoietin-like 3 (ANGPTL3) siRNA agent comprising (i) a sense strand having the sequence:
[M]-mC mU mA mC mA mU fA fU fA mA mA mC mU mA mC mA mA (ps) mG (ps) mU (SEQ ID NO: 11),
and (ii) a antisense strand having the sequence:
mA (ps) fC (ps) mU fU mG fU mA fG mU fU mU fA mU fA mU fG mU (ps) fA (ps) mG (SEQ ID NO: 5),
where [M] is a triantennary ligand moiety linked to the 5′ end of the sense strand and has the structure:
or a pharmaceutically acceptable salt thereof.

### Claim 2

(canceled)

### Claim 3 (depends on 1)

A pharmaceutical composition comprising the ANGPTL3 siRNA agent of claim 1, or a pharmaceutically acceptable salt thereof.

### Claim 4 (depends on 1)

A method of treating, or reducing the risk, of a cardiometabolic disease comprising administering to a person suffering from or at risk of said disease, a therapeutically effective amount of the ANGPTL3 siRNA agent of claim 1, or a pharmaceutically acceptable salt thereof.

### Claim 5 (depends on 4)

The method of claim 4, wherein said cardiometabolic disease is hypertriglyceridemia, obesity, hyperlipidemia, abnormal lipid and/or cholesterol metabolism, atherosclerosis type I, diabetes mellitus, cardiovascular disease, coronary artery disease, non-alcoholic steatohepatitis, non-alcoholic fatty liver disease, homozygous and heterozygous familial hypercholesterolemia, or statin resistant hypercholesterolemia.

### Claim at position 6

6-18. (canceled)

### Claim 19 (depends on 3)

The pharmaceutical composition of claim 3, wherein the composition comprises an admixture with a pharmaceutically acceptable adjuvant, diluent, or carrier.

### Claim 20 (depends on 3)

A method of treating, or reducing the risk, of a cardiometabolic disease comprising, administering to a person suffering from or at risk of said disease, a therapeutically effective amount of the pharmaceutical composition of claim 3, or a pharmaceutically acceptable salt thereof.

### Claim 21 (depends on 20)

The method of claim 20, wherein said cardiometabolic disease is hypertriglyceridemia, obesity, hyperlipidemia, abnormal lipid and/or cholesterol metabolism, atherosclerosis type I, diabetes mellitus, cardiovascular disease, coronary artery disease, non-alcoholic steatohepatitis, non-alcoholic fatty liver disease, homozygous and heterozygous familial hypercholesterolemia, or statin resistant hypercholesterolemia.
